OBJECTIVE: To describe our experience with positioning the Bonebridge (BB) device, a semi-implantable transcutaneous bone conduction implant for patients with conductive and mixed hearing loss as well as for those suffering from single-sided deafness. METHODS: The following is a retrospective case review of 4 adults suffering from conductive or mixed hearing loss and single-sided deafness. The BB device was implanted unilaterally via 2 different approaches selected case by case: the presigmoid transmastoid and the retrosigmoid approach. An audiological evaluation in the free field was conducted to observe the functional benefit with this device. The Glasgow Health Status Inventory (GHSI) and the Glasgow Benefit Inventory (GBI) questionnaires were filled out to evaluate patients' quality of life in relationship to the intervention. RESULTS: No intra- or postoperative complications were observed. The performance in the speech test in all 4 cases reached 100% in the aided condition at 65 dB, while in the unaided condition at 65 dB, it was less than 10%. The GHSI and GBI questionnaires showed an improvement in quality of life after implantation. CONCLUSIONS: The BB device is a safe and effective solution for individuals with pathologies such as chronic otitis media, atresia auris and otosclerosis with inadequate benefit from conventional surgery or bone conduction hearing aids.
OBJECTIVE: To describe our experience with positioning the Bonebridge (BB) device, a semi-implantable transcutaneous bone conduction implant for patients with conductive and mixed hearing loss as well as for those suffering from single-sided deafness. METHODS: The following is a retrospective case review of 4 adults suffering from conductive or mixed hearing loss and single-sided deafness. The BB device was implanted unilaterally via 2 different approaches selected case by case: the presigmoid transmastoid and the retrosigmoid approach. An audiological evaluation in the free field was conducted to observe the functional benefit with this device. The Glasgow Health Status Inventory (GHSI) and the Glasgow Benefit Inventory (GBI) questionnaires were filled out to evaluate patients' quality of life in relationship to the intervention. RESULTS: No intra- or postoperative complications were observed. The performance in the speech test in all 4 cases reached 100% in the aided condition at 65 dB, while in the unaided condition at 65 dB, it was less than 10%. The GHSI and GBI questionnaires showed an improvement in quality of life after implantation. CONCLUSIONS: The BB device is a safe and effective solution for individuals with pathologies such as chronic otitis media, atresia auris and otosclerosis with inadequate benefit from conventional surgery or bone conduction hearing aids.
Authors: Sébastien Schmerber; O Deguine; M Marx; P Van de Heyning; O Sterkers; I Mosnier; P Garin; B Godey; C Vincent; F Venail; M Mondain; A Deveze; J P Lavieille; A Karkas Journal: Eur Arch Otorhinolaryngol Date: 2016-07-30 Impact factor: 2.503
Authors: Pietro Canzi; Irene Avato; Millo Beltrame; Giovanni Bianchin; Marco Perotti; Lorenzo Tribi; Barbara Gioia; Federico Aprile; Stefano Malpede; Andrea Scribante; Marco Manfrin; Marco Benazzo Journal: Acta Otorhinolaryngol Ital Date: 2021-02 Impact factor: 2.124
Authors: Katarzyna B Cywka; Piotr H Skarzynski; Bartlomiej Krol; Stavros Hatzopoulos; Henryk Skarzynski Journal: Eur Arch Otorhinolaryngol Date: 2022-02-19 Impact factor: 3.236
Authors: Friedrich Ihler; Jenny Blum; Max-Ulrich Berger; Bernhard G Weiss; Christian Welz; Martin Canis Journal: Trends Hear Date: 2016-10-03 Impact factor: 3.293